https://www.youtube.com/watch?v=O9dj1s3N4cE
Adam Alonzi has made another excellent film about the power of gene therapy.
Narrated and produced by Adam Alonzi. Music arranged by Leslee Frost. Sponsored by BioViva Sciences Inc.
Continue reading “BioViva Presents: Alzheimer’s Disease and Gene Therapy” »
Nice interview by The Longevity Reporter about BioViva Sciences Inc.
Liz Parrish isn’t your average CEO. A passionate advocate for change, her.
company BioViva is leading the fight for healthy longevity with pioneering.
gene therapies targeting Alzheimer’s, sarcopenia and even aging itself.
Parrish dreams big, but she’s a woman of action. She’s even demonstrated.
her commitment by testing cutting-edge therapies on herself. Could her.
efforts change how we think about aging? Is gene therapy the future or are.
we moving too fast? We caught up with the woman herself to find out more.
The $1.7 billion investment has finally opened its doors to the public, and the robots are ready to provide patients with a medical experience that’s truly revolutionary.
Hailed as the first fully digital hospital in North America, the Humber River Hospital in Toronto, CA finally opened its doors to the public on October 18. In addition to being equipped with the most advanced technologies, robots currently man several areas of the facility. This includes the radiology area where they facilitate the X-Ray procedure and the chemotherapy area where they mix, prepare, and monitor the drugs being administered to the patients. Before the drugs get to the patients, each package is checked and scanned thoroughly through an information management system to make sure that the patients get the correct treatment. These automated robots will also be assisting the health care staff by carrying and delivering medical supplies and food for patients.
Continue reading “The First Robot Operated Hospital in North America Has Finally Opened” »
As long as they don’t enter the food supply.
First micropigs, now dogs: Scientists in China have used a gene-editing technique to produce the world’s first genetically engineered pooches. Although these two endeavors share scientific roots, with their production aimed at assisting medical research, unlike the teeny tiny pigs, the researchers behind this latest project are not intending to sell their customized animals as pets.
So it probably won’t come as a surprise that the dogs weren’t engineered to be cuter, fluffier or more pocket-sized: they had their DNA tweaked to make them more muscly. The first of many potential edits the team would like to carry out, this was done with the forces in mind.
Continue reading “Scientists Have Genetically Engineered Dogs To Make Them More Muscly” »
To whom it may concern,
Cryonics is a legitimate science-based endeavor that seeks to preserve human beings, especially the human brain, by the best technology available. Future technologies for resuscitation can be envisioned that involve molecular repair by nanomedicine, highly advanced computation, detailed control of cell growth, and tissue regeneration.
With a view toward these developments, there is a credible possibility that cryonics performed under the best conditions achievable today can preserve sufficient neurological information to permit eventual restoration of a person to full health.
This short video (with some fun integrated graphics) is from an interview I did with El Pais (the largest newspaper in Spain). It highlights some of the emerging technologies and approaches which have the potential to shift health, medicine and biopharma from its intermittent and reactive physician-centric mode, to an era of more continuous data and a proactive approach, in which the individual is increasingly empowered and integrated into personalized wellness, diagnosis and therapy. The video is below and some associated thoughts follow:
Diagnostics- Era of the digital black bag: Ranging from an eye, ear and throat exam (from connected devices designed for the patient like CellScope, MedWand and Tyto) to cardiac exams enabled by low cost EKG’s (AliveCor and Kito), digital diagnostics is coming to the home. Some will even do automated interpretations (i.e. the EKG interpreted by the app and send to the cloud), where the diagnosis and management of disease will increasingly be enabled outside of the usual clinic, ER or hospital. Wearable patches that integrate multiple vital signs, such as those developed by Vital Connect and Proteus Digital Health will enable more complex disease management and monitoring with ICU level data (EKG, respiratory rate, temperature, position and more), outside of the clinical environment.
https://www.youtube.com/watch?v=YY7f1t9y9a0
“The world is facing some huge problems. There’s a lot of talk about how to solve them. But talk doesn’t reduce pollution, or grow food, or heal the sick. That takes doing. This film is the story about a group of doers, the elegantly simple inventions they have made to change the lives of billions of people, and the unconventional billionaire spearheading the project.”
Aging is 100% genetic, the reason you go from infant to child to adult to old age.
We need to be scrutinizing Progeria, and the case of the girl who died at 20 and was stuck at the age of a toddler, for the key to the genes that will pause aging. While nanotechnology advances parallel with the cure for all diseases.
Once a bucket of genes linked to aging is removed, the lifespan of cells increases significantly, American scientists discovered during ten years of meticulous research, stressing that the results could be applied to humans.
Continue reading “Key to longevity? Blocking over 200 genes boosts lifespan” »
Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as “the woman who wants to genetically engineer you,” she is a humanitarian, entrepreneur and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA) whose mission is to further scientific understanding of biological complexity and the nature and origins of human disease. She is the founder of BioTrove Investments LLC and the BioTrove Podcasts which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine. She is also the Secretary of the American Longevity Alliance (ALA) a 501©(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine with the aim to get governments to consider aging a disease. I am not a medical doctor or scientist. I can not answer details of therapy. I would like to discuss my experience of creating BioViva, organizing the gene therapies, and then finally being able to administer it to the first human.
BOSTON, Sept. 29, 2015 /PRNewswire/ — Veritas Genetics today announced that the company is making it possible for participants in the Personal Genome Project (PGP) to be among the first to get their whole genome sequenced and interpreted for less than a $1,000.
Led by Veritas Genetics Co-Founder Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Personal Genome Project, PGP is a long-term effort to sequence thousands of complete genomes to enable research into personal genomics and personalized medicine. PGP has more than 16,000 participants worldwide.
The “$1,000 Genome” has long been considered the tipping point when sequencing and interpreting the human genome becomes commonplace and begins to rapidly increase what is known and to dramatically impact healthcare. The catchphrase underscores how far science has come since the actual cost of the Human Genome Project, estimated at $2.7 billion spent over a decade.
